Mainz BioMed N.V.

Mainz Biomed Reports Full Year 2023 Financial Results

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer – Exploring New Laboratory Diagnostic Options

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®

Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

MAINZ BIOMED ESTABLISHES PHYSICIAN-LED LABORATORY EXPANDING SERVICE OFFERING FOR PRIVATELY INSURED PATIENTS IN GERMANY

Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium

Mainz Biomed Provides Year-End Corporate Review 2023

Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees

Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland

Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers

Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast

Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference 

Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering

Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering

Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test

Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA

Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper

Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations

Mainz Biomed Presents Groundbreaking Results of ColoFuture Study

Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark

Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit

Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania

Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology

Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference

Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advance